Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism

SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond

(2018) Russell A. DeBose-Boyd et al.   TRENDS IN BIOCHEMICAL SCIENCES

Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma

(2018) Satoshi Ogura et al.   Oncotarget

Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKA

(2017) Taek-In Oh et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Atorvastatin Decreases HBx-Induced Phospho-Akt in Hepatocytes via P2X Receptors

(2017) Aram Ghalali et al.   MOLECULAR CANCER RESEARCH

Targeting cholesterol transport in circulating melanoma cells to inhibit metastasis

(2017) Yu-Chi Chen et al.   Pigment Cell & Melanoma Research

Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells

(2017) Sin-Ting Wang et al.   Cell Death & Disease

Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis

(2017) Cristina Enríquez-Cortina et al.   Oncotarget

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

(2017) Yang Cheng et al.   Oncotarget

B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway

(2017) Yuchao Li et al.   Journal of Cancer

Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway

(2016) Jinmei Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment

(2016) X. Sun et al.   MOLECULAR CANCER THERAPEUTICS

Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo

(2016) Wanfu Lin et al.   ONCOLOGY REPORTS

Lipid metabolic reprogramming in cancer cells

(2016) S Beloribi-Djefaflia et al.   Oncogenesis

Lovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation – Impact of Ras-/Rho-prenylation

(2015) Sarah Afshordel et al.   PHARMACOLOGICAL RESEARCH

The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer

(2015) Jessica E. Stine et al.   Oncotarget

Antitumor Effects and Mechanism of Novel Emodin Rhamnoside Derivatives against Human Cancer Cells In Vitro

(2015) Jie-yu Xing et al.   PLoS One

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

STAT3 Target Genes Relevant to Human Cancers

(2014) Richard Carpenter et al.   Cancers

Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3

(2013) Aruljothi Subramaniam et al.   BRITISH JOURNAL OF PHARMACOLOGY

Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets

(2013) WEI ZHANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

(2013) Gary K Schwartz et al.   LANCET ONCOLOGY

Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway

(2013) Zhiqing Fang et al.   PLoS One

The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics

(2013) Pedro M. R. Cruz et al.   Frontiers in Pharmacology

Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: Roles of apoptotic cell death and LS1034 tumor xenografts model

(2012) Yi-Shih Ma et al.   FOOD AND CHEMICAL TOXICOLOGY

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Targeting apoptosis pathways in cancer by Chinese medicine

(2010) Min Li-Weber   CANCER LETTERS

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

(2010) Yevgeniy Balagula et al.   INVESTIGATIONAL NEW DRUGS

Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo

(2009) Wang Chun-Guang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

(2009) Hung Huynh et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)

(2009) Hung Huynh et al.   JOURNAL OF HEPATOLOGY

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

(2009) Kuen-Feng Chen et al.   JOURNAL OF HEPATOLOGY

Molecular therapy for the treatment of hepatocellular carcinoma

(2008) T F Greten et al.   BRITISH JOURNAL OF CANCER

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE